<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Brocco D</submitter><funding>Italian Ministry of University and Research (MIUR), "Progetti di Ricerca di Interesse Nazionale" (PRIN)</funding><funding>University "G.d'Annunzio" of Chieti-Pescara, "Search for Excellence 2020" to P.S.&amp;quot;</funding><pagination>4748</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9562679</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(19)</volume><pubmed_abstract>Pancreatic cancer (PC) is one of the leading causes of cancer-related death worldwide. Identification of novel tumor biomarkers is highly advocated in PC to optimize personalized treatment algorithms. Blood-circulating extracellular vesicles hold promise for liquid biopsy application in cancer. We used an optimized flow cytometry protocol to study leukocyte-derived EVs (CD45+) and PD-L1+ EVs in blood from 56 pancreatic cancer patients and 48 healthy controls (HCs). Our results show that PC patients presented higher blood levels of total EVs (&lt;i>p&lt;/i> = 0.0003), leukocyte-derived EVs (LEVs) (&lt;i>p&lt;/i> = 0.001) and PD-L1+ EVs (&lt;i>p&lt;/i> = 0.01), as compared with HCs. Interestingly, a blood concentration of LEVs at baseline was independently associated with improved overall survival in patients</pubmed_abstract><journal>Cancers</journal><pubmed_title>High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study.</pubmed_title><pmcid>PMC9562679</pmcid><funding_grant_id>2017EKMFTN_005</funding_grant_id><funding_grant_id>CUP D59C20000680005</funding_grant_id><pubmed_authors>Zappacosta B</pubmed_authors><pubmed_authors>De Tursi M</pubmed_authors><pubmed_authors>Luisi D</pubmed_authors><pubmed_authors>Marchisio M</pubmed_authors><pubmed_authors>Di Sebastiano P</pubmed_authors><pubmed_authors>De Bellis D</pubmed_authors><pubmed_authors>Veschi S</pubmed_authors><pubmed_authors>Brocco D</pubmed_authors><pubmed_authors>Cama A</pubmed_authors><pubmed_authors>Di Mola FF</pubmed_authors><pubmed_authors>De Fabritiis S</pubmed_authors><pubmed_authors>Di Marino P</pubmed_authors><pubmed_authors>Angelone A</pubmed_authors><pubmed_authors>Lanuti P</pubmed_authors><pubmed_authors>Grassadonia A</pubmed_authors><pubmed_authors>Di Gregorio P</pubmed_authors><pubmed_authors>Lellis L</pubmed_authors><pubmed_authors>Simeone P</pubmed_authors><pubmed_authors>Florio R</pubmed_authors><pubmed_authors>Grottola T</pubmed_authors><pubmed_authors>Caporale M</pubmed_authors><pubmed_authors>Verginelli F</pubmed_authors><pubmed_authors>Tinari N</pubmed_authors></additional><is_claimable>false</is_claimable><name>High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study.</name><description>Pancreatic cancer (PC) is one of the leading causes of cancer-related death worldwide. Identification of novel tumor biomarkers is highly advocated in PC to optimize personalized treatment algorithms. Blood-circulating extracellular vesicles hold promise for liquid biopsy application in cancer. We used an optimized flow cytometry protocol to study leukocyte-derived EVs (CD45+) and PD-L1+ EVs in blood from 56 pancreatic cancer patients and 48 healthy controls (HCs). Our results show that PC patients presented higher blood levels of total EVs (&lt;i>p&lt;/i> = 0.0003), leukocyte-derived EVs (LEVs) (&lt;i>p&lt;/i> = 0.001) and PD-L1+ EVs (&lt;i>p&lt;/i> = 0.01), as compared with HCs. Interestingly, a blood concentration of LEVs at baseline was independently associated with improved overall survival in patients</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Sep</publication><modification>2025-05-29T22:29:39.86Z</modification><creation>2025-05-29T22:29:39.86Z</creation></dates><accession>S-EPMC9562679</accession><cross_references><pubmed>36230671</pubmed><doi>10.3390/cancers14194748</doi></cross_references></HashMap>